1. Introduction {#s0005}
===============

Major surgery is associated with a systemic inflammatory cascade that is thought, in some cases, to contribute to transient and/or sustained cognitive decline, possibly through neuroinflammatory mechanisms ([@b0005], [@b0105], [@b0290], [@b0295], [@b0370], [@b0375], [@b0415]). Following surgical trauma, the innate immune system is activated and releases peripheral proinflammatory cytokines. These proinflammatory cytokines in turn disrupt the permeability of blood--brain barrier (e.g., via upregulation of cyclooxygenase 2 isozyme; [@b0355]) due to endothelial dysfunction, allowing them and leukocytes to enter the central nervous system. This causes circulating leukocytes that results in a cycle of neuroinflammation via cytokine expression and microglial activation. In addition, it is also possible for peripheral cytokines to enter the brain via activation of the vagus nerve or through the circumventricular regions ([@b0410]). Notably, cytokine elevation in the central nervous system following surgery has been associated with cognitive dysfunction in humans, broadly in domains of attention, memory, and executive functions ([@b0200], [@b0255]). Moreover, recent meta-analytic evidence identified significantly elevated levels of plasma C-reactive protein (CRP) and interleukin-6 (IL-6) in patients who developed post-operative delirium compared with control patients ([@b0280]), supporting the key role of proinflammatory cytokines in the pathogenesis of delirium following surgery.

The relationship between surgery, peripheral and central inflammation, and post-operative cognitive outcomes has been robustly demonstrated using animal models (e.g., [@b0055], [@b0100], [@b0140], [@b0210], [@b0275], [@b0390], [@b0455], [@b0465], [@b0470]). However, much less evidence for these processes has been identified in humans, primarily owing to limitations of *in vivo* biomarkers of neuroinflammation which vary in sensitivity, specificity, validity, and reliability. Recent evidence points toward elevated levels of proteins such as S100B ([@b0205]) and soluble triggering receptor expressed on myeloid cells 2 (TREM2) ([@b0185]) in cerebrospinal fluid (CSF) in patients with Alzheimer's disease exhibiting symptoms of post-operative delirium (i.e., an acute state of confusion with fluctuating symptoms of disturbed attention and cognition; [@b0080], [@b0295]). Additionally, a host of other CSF and peripheral inflammatory biomarkers also change post-operatively, including CSF monocyte chemoattractant protein 1 and various interleukins ([@b0070], [@b0085], [@b0095], [@b0130], [@b0200], [@b0345], [@b0385], [@b0430]) as well as CRP ([@b0125], [@b0420], [@b0435]). However, current evidence is mixed, with several studies reporting inconsistent findings, likely due to small sample sizes ([@b0060], [@b0170], [@b0445]).

In addition to CSF biomarkers, it is now possible to examine neuroinflammation *in vivo* using positron emission tomography (PET) radiotracers such as \[^11^C\]PBR28 that bind to the translocator protein 18kDa (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR). TSPO is highly expressed in activated microglia and to a lesser degree in reactive astrocytes ([@b0075], [@b0270]) and thus is typically considered an imaging biomarker of neuroinflammation ([@b0010], [@b0025], [@b0090], [@b0285]). \[^11^C\]PBR28 has been used to study neurodegenerative diseases including Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis ([@b0030], [@b0190]; also reviewed in [@b0135]). Unlike CSF biomarkers, imaging biomarkers of neuroinflammation such as \[^11^C\]PBR28 might enable the localization of the inflammatory response, which could provide insights into abnormalities of brain regions or systems that contribute to cognitive complications following surgery. However, there exist very little data attempting to associate PET tracers of neuroinflammation following surgery to post-operative cognitive outcomes.

To our knowledge, only one published study has investigated neuroinflammation using \[^11^C\]PBR28 in the context of surgery ([@b0150]). The authors measured TSPO expression in the brain via \[^11^C\]PBR28 PET in a sample of older adult patients (*N* = 8, all males) undergoing abdominal surgery under general anesthesia on three occasions: 1--3 days prior to surgery, on post-operative days 3--4, and again 3 months after surgery. The authors identified global downregulation of gray matter \[^11^C\]PBR28 binding 3--4 days post-operatively compared with pre-operative baseline, followed at 3 months by a return to or, in some cases, an increase above baseline. Patients showing a greater increase in \[^11^C\]PBR28 binding in the lateral frontal cortex from postoperative days 3--4 to 3 months also showed a greater decrease in cognitive performance (i.e., slower response times) on a test of executive function. It is important to note, however, that general anesthesia might be associated with reductions in \[^11^C\]PBR28 binding to TSPO in the human brain ([@b0195]), thus leaving unclear whether [@b0150] findings reflect an effect of surgery per se vs. general anesthesia.

In the present study, \[^11^C\]PBR28 PET and magnetic resonance (MR) brain imaging, CSF, and blood plasma biomarkers of inflammation were assessed pre-operatively and approximately 1-month post-operatively in a cohort of patients undergoing major orthopedic surgery under spinal anesthesia (for a detailed description of the study design and protocol, see [@b0215]). This study builds upon prior work by investigating the effect of surgery on \[^11^C\]PBR28 binding in a group of older adults of both sexes over the age of 70, who are at increased risk for post-operative cognitive decline. We focused on the investigation of imaging biomarkers of inflammation, with the following goals: **(1)** to determine whether changes in \[^11^C\]PBR28 binding are observed 1 month following surgery in a larger sample, and **(2)** to examine the possible association between symptoms of post-operative delirium and \[^11^C\]PBR28 binding. Based on prior work, we hypothesized that **(H1)** widespread changes in \[^11^C\]PBR28 binding in the brain would be identified between pre-operative baseline and at 1-month post-operative follow-up. If there was sustained neuroinflammation occurring at 1 month following surgery, we would expect to see *increased* \[^11^C\]PBR28 binding. Conversely, if a transient state of immunosuppression was still active at 1 month following surgery, we would expect to see *decreased* \[^11^C\]PBR28 binding. We further hypothesized that **(H2)** those patients with post-operative delirium would show elevated levels of \[^11^C\]PBR28 binding in the brain following surgery, relative to patients who do not develop post-operative delirium.

2. Materials and methods {#s0010}
========================

The overall design and protocol of the study have been described in detail elsewhere ([@b0215]), and will be briefly reported here.

2.1. Participants {#s0015}
-----------------

The Role of Inflammation after Surgery for Elders (RISE) study was a prospective cohort of 65 older adults undergoing elective total joint arthroplasty under spinal anesthesia. Of this larger pool of patients, we analyzed data obtained from 36 patients (30 females, 6 males; knee \[*n* = 17\] or hip \[*n* = 19\]) who had undergone PET/MR imaging and phlebotomy both at pre-operative baseline (PREOP) and at 1-month follow-up (PO1MO)[4](#fn4){ref-type="fn"}. All patients were cognitively normal older adults, as determined by a series of neuropsychological tests at baseline assessing cognitive abilities in domains of memory, learning, attention, and executive functioning, which were used to compute the composite General Cognitive Performance (GCP) score ([@b0260]) following our previous investigations ([@b0125], [@b0360], [@b0365], [@b0430]). All patients had delirium assessments completed daily throughout hospitalization and also at PO1MO. A subset of these patients also had sampling of CSF at PREOP (*n* = 30) and/or PO1MO (*n* = 29). Demographic and clinical characteristics for the included RISE participants are summarized in [Table 1](#t0005){ref-type="table"}.Table 1Demographic and clinical characteristics of the study participants (*N* = 36).All (*N* = 36)Non-delirious (*n* = 30)Delirious (*n* = 6)Group difference (*p*)Age at surgery (years)74.4 ± 3.974.3 ± 3.774.7 ± 5.30.808Education (years)16.0 ± 3.315.7 ± 3.417.3 ± 2.10.281Female sex (*n*, %)30, 83%25, 83%5, 83%1Proportion of knee/hip surgery17 (47%)/19(53%)13 (43%)/17 (57%)4 (67%)/2 (33%))0.296Duration of anesthesia (mins)146.6 ± 32.4141.1 ± 26.2174.5 ± 47.50.019Duration of surgery (mins)92.9 ± 29.089.0 ± 27.5112.7 ± 30.40.067Estimated blood loss (cc)203.5 ± 115.3200.8 ± 123.3216.7 ± 68.30.764Total length of stay (days)3.4 ± 0.93.3 ± 0.94.2 ± 1.00.037GCP (PREOP/PO1MO)61.5 ± 8.9/59.8 ± 9.362.4 ± 8.2/61.2 ± 8.356.1 ± 11.9/52.7 ± 11.20.148/0.037GDS (*n*, % ≥ 6)3, 0.083%1, 0.03%2, 33%-\*CAM-S Peak3.1 ± 2.32.3 ± 1.26.8 ± 3.1\<0.001CAM-S Sum5.6 ± 6.23.9 ± 2.714.2 ± 11.2\<0.001Mean GM SUV~60-90~ (PREOP/PO1MO)1.0 ± 0.3/0.8 ± 0.21.1 ± 0.3/0.8 ± 0.20.9 ± 0.3/0.7 ± 0.20.118/0.230Mean WM SUV~60-90~ (PREOP/PO1MO)0.9 ± 0.2/0.7 ± 0.20.9 ± 0.2/0.7 ± 0.20.8 ± 0.3/0.7 ± 0.10.149/0.309Mean CSF SUV~60-90~ (PREOP/PO1MO)0.7 ± 0.2/0.7 ± 0.20.8 ± 0.2/0.7 ± 0.20.6 ± 0.2/0.6 ± 0.10.051/0.176[^4]

Eligibility criteria for the RISE study enrollment required that each patient be 70 years of age or older, English speaking, and scheduled for hip or knee arthroplasty with planned spinal anesthesia conducted at the Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women's Hospital (BWH), and Brigham and Women's Faulkner Hospital (BWFH), all in Boston, MA. Inclusion criteria also required planned admission for at least 24 h and surgery scheduled at least 15 days in advance, to allow for baseline assessment and \[^11^C\]PBR28 PET/MR scan. Total hip and knee arthroplasties were targeted because of their delirium risk and frequent use of spinal anesthesia ([@b0080]), to avoid the potential confound of general anesthesia ([@b0195]). Exclusion criteria included any active psychiatric disorders, total blindness, and contraindication to spinal anesthesia/lumbar puncture, MRI, or \[^11^C\]PBR28 PET (for details, see [@b0215]). Importantly, all prospective patients were genotyped for the Ala147Thr polymorphism in the TSPO gene and those with predicted low-binding affinity for \[^11^C\]PBR28 (Thr/Thr) ([@b0265], [@b0325]) were excluded. PET/MR data at both time points were collected at the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital (MGH), Boston, MA. CSF data were obtained during the initiation of spinal anesthesia in the immediate pre-operative period at BIDMC, BWH, and BWFH; and at 1-month follow up at MGH. The Institutional Review Board of Partners Healthcare System (MGH, BWH, BWFH) approved all study procedures, with ceded review from BIDMC and Hebrew SeniorLife, the study coordinating center.

2.2. Neuropsychological and delirium assessment {#s0020}
-----------------------------------------------

Prior to the pre-operative baseline assessment, trained research staff conducted pre-screening evaluations involving telephone interview, medical record review, and safety screening for lumbar puncture and PET/MR imaging. The baseline face-to-face interview was performed in each patient's home, which involved complete neuropsychological testing and delirium assessment. During their hospital stay, patients were assessed daily with 10--15 min interviews, which included brief cognitive testing and an adapted Delirium Symptom Interview ([@b0015]) to rate delirium using the Confusion Assessment Method (CAM) ([@b0245]) and CAM-Severity (CAM-S) scoring ([@b0235]). The presence of delirium was determined by the CAM diagnostic algorithm, a standardized approach with high sensitivity (94--100%), specificity (90--95%) ([@b0440], [@b0450]), and reliability. A follow-up interview with complete neuropsychological testing was conducted at 1 month after hospitalization. For a full list of measures collected during these sessions, see [@b0215]). Delirium severity was determined using the CAM-S long form, which is based on the 10 features from the long CAM instrument to quantify the intensity of delirium features ([@b0235]). Scores on the CAM-S long form range from 0 to 19, with higher scores indicative of more severe delirium. Delirium severity was measured in the present study for each patient using both CAM-S peak (the highest single CAM-S rating observed during hospitalization) and CAM-S sum (the summed score across all hospital days), thereby capturing both delirium intensity and duration ([@b0425]).

2.3. PET/MR data acquisition {#s0025}
----------------------------

At pre-operative baseline (PREOP) and post-operative 1-month follow-up (PO1MO), all patients underwent integrated PET/MR scans using \[^11^C\]PBR28 as the radiotracer. Data were acquired on a Biograph mMR scanner (Siemens Healthineers, Erlangen, Germany) with a 16-channel head and neck receiver coil. \[^11^C\]PBR28 was synthesized on site ([@b0225]) and was administered as a slow bolus injection through an intravenous catheter. The mean (±standard deviation) dose of the radioligand was 535.02 ± 13.32 MBq for PREOP and 508.38 ± 72.15 MBq for PO1MO. PET images were acquired in list mode format for 60 min beginning 30 min post-injection. Simultaneously, 60 min of MRI data were collected using several sequences. Relevant to this study, morphological MR data were acquired using a T1-weighted 3D multi-echo magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (repetition time \[TR\] = 2530 ms, echo time \[TE~1-4~\] = 1.69/3.55/5.41/7.27 ms, inversion time \[TI\] = 1100 ms, flip angle = 7°, 256 mm field of view \[FOV\], 176 × 256 in-plane matrix, 1 mm isotropic voxels). Due to practical constraints, no arterial blood samples were acquired during the acquisition of PET/MR data.

2.4. PET/MR data analysis {#s0030}
-------------------------

PET images were reconstructed using the Ordinary Poisson Ordered Subset Expectation Maximization 3D algorithm (3 iterations, 21 subsets, 344 × 344 image matrix, with 2.1 mm in-plane pixel size and 2.0 mm slice thickness; 4 mm Gaussian filter) and applying all the required corrections using standard methods provided by the manufacturer. The head photon attenuation map was estimated from each patient's MPRAGE volume using a combination of intensity- and prior-based tissue segmentation and atlas registration ([@b0250]). \[^11^C\]PBR28 PET uptake images obtained from the data acquired 60--90 min post-radioligand injection were normalized to the injected dose and patient weight to obtain standardized uptake values (SUV~60-90~). We chose to use non-intensity-normalized SUV because of the within-subject nature of our study design and given the expectation that the signal changes due to surgery would be a global effect ([@b0150]). Each patient's MPRAGE data were used for automated volumetric segmentation of cortical and subcortical brain structures via the FreeSurfer image analysis suite, which is documented and freely available for download online (version 6.0, <https://surfer.nmr.mgh.harvard.edu/>). To correct for any head motion potentially occurring between the collection of the MPRAGE volume and PET data, the SUV~60-90~ image was co-registered to the T1 image acquired at the same time point for each patient.

*Whole-brain voxel-wise analysis.* To perform voxel-wise analysis of SUV data at the group level comparing the two time points, we normalized each patient's SUV~60-90~ images to MNI152 space via a combined volumetric and surface registration algorithm, which is particularly sensitive to both cortical and subcortical alignment ([@b0475]). The resulting spatially-normalized (resampled to 2 mm isotropic voxels) images were skull-stripped and volumetrically smoothed using a full width at half maximum (FWHM) of 8 mm. Finally, we performed group-level random-effects *t*-tests on these images in SPM12 (version 7487, <https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>) to identify brain regions exhibiting significant changes in \[^11^C\]PBR28 binding between PREOP and PO1MO. A voxel-wise intensity threshold of *p* \< .005 corrected for family-wise error rate was used to assess statistical significance.

*Regions of interest (ROI) analysis.* As noted above, we predicted that major surgery would be associated with widespread changes in \[^11^C\]PBR28 binding in the brain. Nevertheless, complementing the voxel-wise analysis in standard template space, we additionally analyzed SUV data in each patient's native space to characterize changes in \[^11^C\]PBR28 binding between the time points with increased anatomical specificity. Such combination of whole-brain voxel-wise and ROI-based analyses are consistent with the approach employed in previous investigations from our groups (e.g., [@b0035]) and others ([@b0150]) performing within-subject comparisons of brain \[^11^C\]PBR28 uptake. Based on each patient's high-resolution tissue segmentation derived by the standard Desikan-Killany atlas in FreeSurfer ([@b0115]), the symmetric geometric transfer matrix (GTM) method was used to correct for spill-in and spill-out effects between adjacent brain tissue types ([@b0160], [@b0165]). The mean SUV~60-90~ was computed for each of the 48 individual ROIs (averaged across hemispheres), which was then used to compute the weighted mean SUV~60-90~ of cortical/subcortical gray matter, white matter, and CSF, separately for PREOP and PO1MO. We then performed repeated-measures analyses of variance (ANOVAs) and *t*-tests to evaluate regional variability and specificity in the magnitude of changes in \[^11^C\]PBR28 binding between PREOP and PO1MO.

Furthermore, to examine the effect of post-operative delirium on \[^11^C\]PBR28 binding, we also conducted ROI-based analyses comparing delirious and non-delirious participants. Given the unequal group size, we first identified two subsets of non-delirious participants matched to the delirious group on sex and age (delirious: *M*~age~ = 74.7, *SD*~age~ = 5.3; non-delirious~1~: *M*~age~ = 75.8, *SD*~age~ = 2.5; non-delirious~2~: *M*~age~ = 77.3, *SD*~age~ = 6.1; 5 females in all groups). The delirious group did not differ in age from either non-delirious group (non-delirious~1~ *p* = .95, non-delirious~2~ *p* = .54). We then performed a three-way mixed ANOVA with Group (delirious vs. non-delirious), Time point (pre vs. post), and Tissue class (cortex, subcortical gray matter, white matter, and CSF) as factors, comparing the mean SUV~60-90~ separately for each group pair (i.e., delirious vs. non-delirious~1~, delirious vs. non-delirious~2~).

*Correlation analysis.* To explore the possible association between post-operative delirium severity and surgery-related changes in \[^11^C\]PBR28 binding, we calculated across patients the Pearson's *r* between a) peak and sum CAM-S scores, and b) \[^11^C\]PBR28 SUV~60-90~ before surgery, 1 month after surgery, and the change in \[^11^C\]PBR28 SUV~60-90~ from baseline to 1 month after surgery.

2.5. Immunoassays {#s0035}
-----------------

*Specimen collection and storage.* Immediately prior to the radiotracer injection at each time point, 20 mL of blood was collected into one heparinized and one ethylenediaminetetraacetic acid (EDTA) tube (10 mL in each). During processing, plasma and cellular material were separated using low-speed centrifugation (1500 relative centrifugal force) and stored at −80 °C. CSF was acquired in the immediate pre-operative period during induction of spinal anesthesia (PREOP) and at PO1MO via lumbar puncture. CSF was collected by aspiration or dropwise collection directly into the collection tubes. To minimize potential contamination of CSF sample with blood, the sample was centrifuged at 1000 relative centrifugal force for 10 min to separate before storage in 0.5 mL aliquot tubes at −80 °C. Samples were stored at −80 °C in polypropylene tubes until analyzed.

*Protein measurement.* Plasma and CSF concentrations of the inflammatory proteins CRP, IL-6, and Chitinase 3-Like 1 glycoprotein (CHI3L1, also known as YKL-40 \[tyrosine (Y), lysine (K), leucine (L) with molecular weight of 40\]) from heparinized plasma and CSF samples at PREOP and PO1MO were measured via enzyme-linked immunosorbent assay (ELISA) platforms (Ella System, ProteinSimple, San Jose, CA; Meso Scale Discovery \[MSD\], Gaithersburg, MD). Plasma and CSF biomarkers of inflammatory response were analyzed via *t*-tests corrected for multiple comparisons. We also performed exploratory correlation analyses between gray matter SUV~60-90~ and plasma and CSF analytes.

*Correlation analysis*. To explore the possible link between the observed change in \[^11^C\]PBR28 binding and plasma/CSF biomarkers of inflammation, we performed a series of correlation analyses. For these analyses, we calculated the mean change in \[^11^C\]PBR28 SUV~60-90~ in gray matter (ΔSUV~60-90~) as well as the change in plasma and CSF concentrations of the three aforementioned inflammatory proteins.

3. Results {#s0040}
==========

3.1. Decreased brain binding of \[^11^C\]PBR28 following surgery {#s0045}
----------------------------------------------------------------

A paired *t*-test comparing the SUV~60-90~ images between the two time points revealed a number of regions exhibiting significant differences, including the thalamus, pons, cerebellum, medial frontal cortex, posteromedial cortex, middle and inferior frontal gyrus/insula, primary sensory and motor cortices, and superior temporal gyrus ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1\[^11^C\]PBR28 SUV~60-90~ images and statistical maps identifying differences between pre-operative and post-operative scans. The top and middle rows identify the mean \[^11^C\]PBR28 SUV~60-90~ images for the pre-operative baseline (PREOP) and post-operative 1-month follow-up visit (PO1MO), respectively, which are projected onto a high-resolution Montreal Neurological Institute (MNI152) template. The bottom row identifies brain regions exhibiting significantly reduced \[^11^C\]PBR28 binding for PO1MO compared with PREOP at pFWE \< 0.005. For visualization purposes only, the SUV~60-90~ images and statistical maps were upsampled to match the underlay template resolution.

To complement the whole-brain voxel-wise analysis, we carried out ROI analysis to investigate the variability of the post-operative change in \[^11^C\]PBR28 binding across different brain tissue classes. A two-way ANOVA with tissue class and time point as factors revealed a significant main effect of tissue class \[*F*(3, 105) = 123.00, *p* \< .001, η~p~^2^ = 0.778\], of time point (\[*F*(1, 35) = 30.94, *p* \< .001, η~p~^2^ = 0.469\]), and a significant interaction between tissue class and time point (\[*F*(3, 105) = 38.43, *p* \< .001, η~p~^2^ = 0.523\]) ([Fig. 2](#f0010){ref-type="fig"}). To further interpret this interaction effect, we computed ΔSUV~60-90~ (i.e., PREOP -- PO1MO) for each tissue class and analyzed the difference via post-hoc *t*-tests (Bonferroni corrected α = 0.05/6 tests = 0.008). The mean ± *SD* ΔSUV~60-90~ for each tissue class were as follows: Cortical gray matter (0.21 ± 0.21), subcortical gray matter (0.21 ± 0.22), white matter (0.17 ± 0.19), and CSF (0.11 ± 0.15). This analysis revealed that the mean ΔSUV~60-90~ was significantly different between every pair of tissue classes, except for cortical vs. subcortical gray matter (*p* = .955). Across all tissue classes, we observed a significant reduction in SUV~60-90~ from PREOP to PO1MO ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Mean \[^11^C\]PBR28 SUV~60-90~ in the four major tissue classes. *N* = 36. SUV = standardized uptake values, PREOP = pre-operative baseline, PO1MO = post-operative 1-month follow-up, GM = gray matter, WM = white matter, CSF = cerebrospinal fluid. Error bars represent the standard error of the mean. The difference between PREOP and PO1MO is significant at *p* \< .001 for every tissue class.

Next, we calculated the mean SUV~60-90~ for each individual ROI based on the standard Desikan-Killany atlas in FreeSurfer ([@b0115]) assembled into the GTM volumetric segmentation ([@b0160]), which was then averaged across the hemispheres. A series of paired *t*-tests (Bonferroni corrected α = 0.05/48 tests = 0.001) revealed significant reduction in \[^11^C\]PBR28 binding in all regions, with the entorhinal cortex and CSF being the only ROIs that did not formally survive the threshold for significance after correction for multiple comparisons (*p*'s = 0.0015 and 0.008, respectively) ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Mean \[^11^C\]PBR28 SUV~60-90~ and percent signal change in individual gray matter, white matter, and CSF regions of interest. The point and line plots on the left panel illustrate the magnitude of \[^11^C\]PBR28 SUV~60-90~ at pre-operative baseline (PREOP) and 1-month post-operative follow-up (PO1MO) in various regions of interest (ROIs) across the brain. These ROIs are rank-ordered by the magnitude of change in \[^11^C\]PBR28 SUV~60-90~ across the two timepoints expressed as percent, i.e., (PREOP -- PO1MO) / PREOP × 100, from largest (top) to smallest (bottom). The corresponding % signal change for each ROI is depicted on the right panel. *N* = 36. Error bars represent the standard error of the mean.

3.2. Effect of post-operative delirium severity {#s0050}
-----------------------------------------------

Six patients developed delirium post-operatively (assessed during hospitalization); the delirium ratings were negative for all patients at post-operative 1-month follow-up. Characteristics of the non-delirious (*n* = 30) vs. delirious (*n* = 6) patients are summarized in [Table 1](#t0005){ref-type="table"}. To examine potential group differences in \[^11^C\]PBR28 binding, we first conducted a three-way mixed ANOVA with Group (delirious vs. non-delirious), Time point (pre vs. post), and Tissue class (cortex, subcortical gray matter, white matter, and CSF) as factors. Results revealed neither a significant main effect of Group nor interactions involving this factor, suggesting that post-operatively delirious participants and non-delirious participants had similar \[^11^C\]PBR28 binding regardless of time point or tissue type ([Table 2](#t0010){ref-type="table"} and [Table 3](#t0015){ref-type="table"}).Table 2Mean \[^11^C\]PBR28 SUV~60-90~ in the four major tissue classes by delirium groups.DeliriousNon-delirious~1~Non-delirious~2~*PREOP*Cortex0.85 ± 0.320.92 ± 0.130.99 ± 0.23Subcort. GM0.86 ± 0.300.96 ± 0.141.03 ± 0.22WM0.77 ± 0.260.81 ± 0.100.89 ± 0.15CSF0.61 ± 0.200.73 ± 0.120.76 ± 0.18*PO1MO*Cortex0.69 ± 0.170.81 ± 0.210.82 ± 0.16Subcort. GM0.72 ± 0.130.83 ± 0.190.85 ± 0.14WM0.65 ± 0.100.71 ± 0.140.75 ± 0.12CSF0.56 ± 0.080.66 ± 0.130.65 ± 0.13[^5]Table 3Results of three-way mixed analysis of variance.Delirious vs. Non-delirious~1~Delirious vs. Non-delirious~2~Effect*F* (*df*)*p*η^2^~p~*F* (*df*)*p*η^2^~p~Group1.10 (1,10)0.320.11.95 (1,10)0.190.16Time point3.65 (1,10)0.0850.275.29 (1,10)0.040.35Tissue class35.63 (3,30)\<0.0010.7866.67 (3,30)\<0.0010.87Group\*Time point0.01 (1,10)0.910.0010.08 (1,10)0.790.01Group\*Tissue class0.82 (3,30)0.490.080.46 (3,30)0.710.04Time point\*Tissue class8.11 (3,30)\<0.0010.457.84 (3,30)0.0010.44Group\*Time point\*Tissue class0.98 (3,30)0.420.091.22 (3,30)0.320.11

To explore the possible association between the magnitude of \[^11^C\]PBR28 binding and severity of post-operative delirium, we calculated the Pearson's *r* between the mean gray matter SUV~60-90~ (computed based on all cortical and subcortical regions) and the CAM-S ratings. Following our previous work ([@b0340]), we examined both CAM-S peak and sum scores. Upon visual inspection of scatter plots, we observed heteroscedasticity across the patient subgroups (i.e., delirious and non-delirious). Therefore, correlation analyses were performed separately for the non-delirious and delirious groups. These analyses identified no significant relationship between the mean gray matter SUV~60-90~ and delirium severity in either patient subgroup ([Fig. 4](#f0020){ref-type="fig"}). It is interesting to note, however, that the patient with the most severe delirium symptoms was among those showing the least reduction in \[^11^C\]PBR28 binding following surgery (top right, [Fig. 4](#f0020){ref-type="fig"}).Fig. 4Correlation between delirium severity and \[^11^C\]PBR28 binding in gray matter. Regression lines identify the least-squares fit in the non-delirious (*n* = 30, gray) and delirious (*n* = 6, red) patients. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

3.3. Effect of surgery on plasma and CSF biomarkers of inflammation {#s0055}
-------------------------------------------------------------------

Finally, although our main focus was to examine changes in \[^11^C\]PBR28 binding following surgery, we also performed post hoc exploratory analyses of the plasma and CSF inflammatory biomarkers in the current sample. These analyses focused on plasma and CSF concentrations of three inflammatory proteins (CRP, IL-6, and YKL-40) and their measurements at PREOP and PO1MO. Intriguingly, compared to PREOP, *elevated* post-operative levels of IL-6 and YKL-40 were identified in plasma, and elevated post-operative levels of CRP were identified in CSF ([Table 4](#t0020){ref-type="table"}). To examine the possible link between the observed reduction in \[^11^C\]PBR28 binding in the brain and these inflammatory biomarkers, we performed correlation analyses of gray matter ΔSUV~60-90~ with ΔIL-6 in plasma, ΔYKL-40 in plasma, and ΔCRP in CSF. These analyses identified no significant relationships (gray matter ΔSUV~60-90~ × ΔIL-6 in plasma: *r* = -0.061, *p* = .724; gray matter ΔSUV~60-90~ × ΔYKL-40 in plasma: *r* = -0.068, *p* = .694; gray matter ΔSUV~60-90~ and ΔCRP in CSF: *r* = -0.137, *p* = .517).Table 4Concentrations of inflammatory proteins.PREOPPO1MO*p*-value*Plasma*IL-6 (pg/mL)4.1 ± 1.77.0 ± 6.70.012CRP (pg/mL)7991272.5 ± 12107737.09285735.6 ± 10495969.10.644YKL-40 (pg/mL)95619.8 ± 86595.0152204.2 ± 121945.4\<0.001\**CSF*IL-6 (pg/mL)3.9 ± 1.68.3 ± 23.90.325CRP (pg/mL)15132.4 ± 17809.233586.5 ± 39374.30.039YKL-40 (pg/mL)291233.2 ± 101711.7276455.6 ± 62818.20.401[^6]

4. Discussion {#s0060}
=============

Because of the aging of the population and a burgeoning number of older persons undergoing major surgery ([@b0175], [@b0405]), substantial numbers of people are at risk for post-operative delirium and long-term cognitive decline. Given that neuroinflammation is thought to contribute to the pathogenesis of both ([@b0110], [@b0295], [@b0350], [@b0430]), there is an urgent need to better understand the neural mechanisms underlying the inflammatory response triggered by major surgery, and how this relates to short- and long-term cognitive dysfunction. The present study contributes to the literature by demonstrating in a relatively sizeable sample for this type of imaging that, 1 month following major orthopedic surgery under spinal anesthesia, \[^11^C\]PBR28 binding in the brain is globally downregulated compared with pre-operative baseline. Converging evidence from the whole-brain voxel-wise and ROI analyses suggest that, although some tissue-related and regional variability exist, the observed reduction does not appear to be localized to specific regions. No significant associations were identified between \[^11^C\]PBR28 binding and delirium or between \[^11^C\]PBR28 binding and CSF/plasma biomarkers of inflammation. These findings are discussed further below.

Our whole-brain voxel-wise analysis identified a widespread reduction in \[^11^C\]PBR28 binding from pre-operative baseline to 1-month post-operative follow-up. Global downregulation of brain \[^11^C\]PBR28 binding was similarly identified in a small sample of older adult patients 3--4 days following abdominal surgery under general anesthesia ([@b0150]). This has been interpreted as reflecting a period of anti-inflammatory responses following the initial pro-inflammatory phase and prior to the return to or increase above baseline at 3-month post-operative follow-up. It is therefore possible that the downregulation of \[^11^C\]PBR28 at 1-month post-operative follow-up observed in the present study reflects this state of immunosuppression persistent at this time point following surgery. Notably, there is evidence showing that reduction in \[^11^C\]PBR28 binding might reflect inhibition of neuroprotective microglial activation. In the presence of inflammation or disruption of blood--brain barrier, microglia that are usually inactive can differentiate into one of two activated phenotypes, pro-inflammatory M1 and anti-inflammatory M2 ([@b0155], [@b0305], [@b0380], [@b0395]). This raises the intriguing possibility that higher TSPO levels/\[^11^C\]PBR28 binding do not always reflect a neuroinflammatory response. Indeed, there is evidence demonstrating that M1-predominant microglial activation did not increase TSPO levels in in-vitro human microglia ([@b0320]), whereas M2-predominant microglial activation resulted in overexpression of TSPO in rodent microglial cells ([@b0045]). These findings are in line with the interpretation that downregulation of \[^11^C\]PBR28 binding following surgery might reflect reduced activation or depletion of neuroprotective microglia leading to neuroimmune suppression. Moreover, these finding are also consistent with the conclusion of a recent study in which the authors identified decreased \[^11^C\]PBR28 binding (quantified as total volume of distribution, V~T~) among patients with post-traumatic stress disorder ([@b0065]), a clinical condition typically associated with elevated levels of peripheral inflammatory markers ([@b0335]). Post-operative impairments in immune activity have important clinical implications as they are associated with a heightened risk of developing post-operative infections and sepsis ([@b0020], [@b0315]). The current results shed light on the potential importance of developing pharmacological interventions aimed at restoring microglial activation subserving neuroimmune system function during a post-operative recovery period.

Alternatively, the present findings may also in part be explained by other possibilities. For instance, in addition to the neuroimmunosuppression account above, it is possible that surgery and/or the use of anesthesia contributed to alterations in mitochondrial physiology. In neonatal rats, exposures to sevoflurane (an inhalational anesthetic commonly used in humans) have been shown to decrease mitochondrial density in hippocampal axon terminals by 20% ([@b0040]). In vitro studies have also confirmed that a number of common general and ancillary anesthetic agents inhibit mitochondrial function ([@b0220]). Given that TSPO is a transmembrane protein located in the outer mitochondrial membrane ([@b0330]), decreased \[^11^C\]PBR28 binding following surgery might reflect reduced mitochondrial activity.

Yet another possibility is that the reduction in \[^11^C\]PBR28 binding might reflect decreased availability of the radioligand passing through blood--brain barrier, thus highlighting the importance of concomitantly assessing plasma concentrations of \[^11^C\]PBR28. SUV is considered a reliable metric of \[^11^C\]PBR28 binding that shows high correlation with V~T~ ([@b0310], [@b0460]), which is the standard for quantification of \[^11^C\]PBR28 binding when arterial plasma data are available ([@b0230]). However, the use of SUV depends on the assumption of no significant differences in radioligand delivery to the brain between time points of interest. It is possible that major surgery and ensuing hospitalization led to changes in brain blood flow, metabolism, protein binding, and/or peripheral TSPO binding, which cannot be completely ruled out as possibilities without arterial plasma sampling. Indeed, one study showed that brain \[^11^C\]PBR28 binding was reduced 4 h following the systemic administration of lipopolysaccharide (LPS; known to induce global inflammatory response) in a sample of non-human primates compared to pre-LPS baseline ([@b0180]). However, when the authors accounted for the radioligand concentration in the arterial plasma, which had decreased to a greater extent due to the robust peripheral metabolism of \[^11^C\]PBR28, whole-brain \[^11^C\]PBR28 binding was found to increase from baseline to 4 h post-LPS. Given this evidence, it is possible that due to prolonged peripheral inflammation at post-operative 1-month follow-up, the amount of \[^11^C\]PBR28 that is available to enter the brain is decreased compared with pre-operative baseline, thus resulting in a relative reduction of \[^11^C\]PBR28 binding. We cannot formally test this possibility given that we were not able to obtain arterial blood samples from the participants in this study due to practical constraints. However, it is important to note that none of the peripheral inflammatory marker levels was significantly correlated with the observed change in gray matter \[^11^C\]PBR28 binding, supporting our interpretation that the observed effects are not merely driven by the limited availability of \[^11^C\]PBR28 to be detected by brain PET. Nevertheless, future work should examine the replicability of the current results through techniques that can account for the aforementioned factors that might influence overall \[^11^C\]PBR28 binding in the brain ([@b0230]).

Contrary to our hypothesis, we did not find evidence in support of a relationship between delirium status or severity and \[^11^C\]PBR28 binding. The small number of patients who developed delirium post-operatively (*n* = 6) made it difficult to examine a potential association with \[^11^C\]PBR28 binding. Future studies should make every effort to balance the distribution of non-delirious vs. delirious cases by, for instance, oversampling patients at higher risk for post-operative delirium based on prior risk stratification approaches ([@b0120], [@b0300]) and neuropsychological characteristics ([@b0145]). Another approach might be to employ a nested case-control study design in which all delirium cases would be studied with a matched set of non-delirious control participants.

Finally, our exploratory analyses of plasma and CSF biomarkers of inflammation identified significant increases in the concentrations of IL-6 and YKL-40 in plasma and of CRP in CSF from pre-operative baseline to post-operative follow-up at 1 month. In our previous work in the Successful Aging after Elective Surgery (SAGES) Study, in which we examined a larger pool of patients (*N* = 566) undergoing wider types of surgery under general or spinal anesthesia ([@b0360], [@b0365]), we did not observe a significant change in plasma IL-6 from pre-operative baseline to post-operative follow-up at 1 month. Instead, among the four time points (at pre-operative baseline, post-anesthesia care unit, post-operative day 2, and post-operative 1-month follow-up), post-operative increases in plasma IL-6 and CRP peaked at post-operative day 2 and then returned to baseline levels at the post-operative 1-month follow-up ([@b0125], [@b0430]). It is unclear why levels of some inflammatory biomarkers remained elevated post-operatively at 1 month in the present sample. It should be noted that the levels of plasma IL-6 at the post-operative 1-month follow-up were comparable to those we previously identified in a larger sample at the same time point ([@b0430]). This allows us to rule out the possibility that the current sample who had undergone \[^11^C\]PBR28 PET scans exhibited particularly sustained levels of peripheral inflammation 1 month following surgery relative to an independent, larger sample. Nevertheless, these seemingly disparate findings underscore the importance of further examining the role of systemic inflammation and neuroinflammation in post-operative delirium, with a particular focus on elucidating the complex relationship between \[^11^C\]PBR28 PET, plasma, and CSF biomarkers of inflammation across different time points. Clarification of this issue is particularly important given that the concentration of YKL-40 in CSF, which has recently emerged as a neuroinflammatory biomarker (reviewed in [@b0050]), did not show changes across time points in the current study.

A few potential limitations of the present study should be acknowledged. Although incidentally, the present sample included a disproportionately greater number of females than males. It is important to note, however, that prior work examining the effect of surgery on \[^11^C\]PBR28 binding in human involved only males ([@b0150]). Thus, our results identifying a significant effect of major orthopedic surgery based on a mixed-sex sample make an important addition to the literature. Nevertheless, future work should make every effort to include similar numbers of females and males in the sample, given recent evidence identifying significant differences between sexes in \[^11^C\]PBR28 binding among healthy subjects ([@b0400]). In addition, ROI analyses comparing differences in \[^11^C\]PBR28 binding revealed that a significant reduction from pre-operative baseline to post-operative 1 month follow up was also observed in CSF, although the magnitude of change was significantly smaller compared with both gray and white matter. This suggests that some of the signal difference observed in the parenchyma may reflect non-specific binding and/or unbound radioligand, which may be due to the limited radioligand availability for the central nervous system as discussed above. It would be critical for future work to obtain dynamic PET data with radiometabolite-corrected arterial input function and a correction for plasma free fraction to address this potential concern. Another important limitation is the lack of information on other medications received in the perioperative period, which may have confounded the results. Finally, despite our use of a well-validated approach for detection, we acknowledge that delirium is a fluctuating condition and any measurement approach may have false negatives, contributing to potential measurement error.

Notwithstanding these potential limitations, the new evidence identified in the present study sheds light on the possible mechanisms through which surgery contributes to prolonged suppression of TSPO expression and highlights the need for future work to assess the time-dependent interaction of central vs. peripheral indices of inflammation as well as its modulation in a balanced sample of delirious and non-delirious participants.
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The one month time period was chosen for a follow-up for both conceptual and logistical reasons. Conceptually, our prior studies have shown cognitive decline at one month post-surgery ([@b0240]), and investigating the possibility of neuroinflammation at this time point appeared relevant. Logistically, patients reported that returning sooner than one month would have been prohibitive due to their rehabilitation needs and mobility concerns during the post-operative period.
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[^2]: Currently at Biogen, Inc., Cambridge, MA, United States.
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[^4]: *Note:* PREOP = pre-operative baseline, PO1MO = post-operative 1-month follow-up, GCP = general cognitive performance, GSD = geriatric depression scale, CAM-S = Confusion Assessment Method-Severity, GM = gray matter, WM = white matter, CSF = cerebrospinal fluid, SUV = standardized uptake values. \**p*-value was not computed due to a small sample size.

[^5]: *Note: n* = 6 (5 females) in all subgroups. PREOP = pre-operative baseline, PO1MO = post-operative 1-month follow-up, subcort. GM = subcortical gray matter, WM = white matter, CSF = cerebrospinal fluid.

[^6]: *Note:* IL-6 = interleukin-6, CRP = C-reactive protein, YKL-40 = also known as CHI3L1 \[Chitinase 3-Like 1 glycoprotein\], PREOP = pre-operative baseline, PO1MO = post-operative 1-month follow-up. \*Significant at *p* \< .008 Bonferroni-corrected for multiple comparisons.
